Research & Diagnostics
Chromosomal translocations with immunoglobin (IG) loci are the classic drivers of many B-cell lymphomas. Detection of these translocations is important for diagnosis, prognosis and therapy decisions.
The current diagnostic standard is FISH, which has limitations in the detection of cryptic fusions and fusion partners, is not suited for multiplexing, and is laborious. The molecular diagnosis of translocations is not addressed well by current NGS methods. RNAseq will not detect IG enhancer fusions, and conventional targeted DNA sequencing methods are less suited to sequence large structural changes.
TLA enables targeted sequencing of all gene fusions including identification of the fusion partner.
TLA multiplex kit for detection of gene fusions in BCL2, BCL6, MYC. This kit can be customized with other genes. Contact us for more information.
Testing for minimal residual disease (MRD) is starting to be implemented for lymphoma patients for patient stratification and to determine prognosis, and monitor treatment efficacy. Clinical studies are ongoing to tailor patient treatment based on MRD levels (Dogliotti I & Ferrero S (2017)).
TLA uniquely enables detection of gene fusion breakpoint sequences at nucleotide resolution. Since gene fusions in lymphoma are known to be cancer-driving, clonal events, these breakpoint sequences are ideal markers for sensitive and quantitative MRD testing with PCR. Review our application note to learn more on TLA and NGS for genomic gene fusion breakpoint sequence specific MRD testing in lymphoma and leukaemia.
Become a testing partner
We are currently further validating this application. Please contact us if you would like to become a testing partner.
- Application notes
Targeted Locus Amplification (TLA): A Novel Next Generation Sequencing (NGS) Technology to Detect New Molecular Markers and Monitoring Minimal Residual Disease (MRD) in Mantle Cell and Follicular Lymphoma
Genuardi E et al. (2017)
A.O.U. Citta della Salute e della Scienza di Torino, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Cergentis, Clinica Humanitas/Gavazzeni, University of Modena e Reggio Emilia & University of Torino
Dogliotti I & Ferrero S (2017)
A.O.U. Citta della Salute e della Scienza di Torino & University of Torino
Macintyre G et al. (2016)
University of Cambridge & VU University Medical Center
Meisel C et al. (2017)
DKFZ, Medical Genetic Center Munich, National Center for Tumor Diseases (NCT), TU Dresden, University Kiel
Toy W et al. (2016)
AstraZeneca, Memorial Sloan Kettering Cancer Center, University of Chicago & University of Illinois at Urbana Champaign
Ter Brugge P et al. (2016)
Bellvitge Biomedical Research Institute Barcelona, Curie Institute, ICREA, Institute of Cancer Research London, The Netherlands Cancer Institute, University of Barcelona & University Medical Center Utrecht
Hastings RJ et al. (2015)
Charles University Prague, CHUV, Great Ormond St Hospital, Gustave Roussy, Hospital del Mar, Institute of Genomic Medicine, Oslo University Hospital, Ospedale di Circolo-Polo Universitario, Our Lady's Children's Hospital, Oxford University Hospitals NHS Trust, Radboud University Medical Center, St James's Hospital, University of Cagliari, University of Groningen, University Hospital Ghent, UZ Leuven, VU University Medical Center
De Vree PJP et al. (2014)
Cergentis, Erasmus Medical Center, Ghent University, Hubrecht Institute-KNAW, Leiden University Medical Center, The Netherlands Cancer Institute, Radboud University Medical Center, University of Amsterdam, University of Groningen, University Medical Center Utrecht & VIB
Applications and principles of TLA-based complete gene sequencing and haplotyping